Strategies for developing Ki67 as a useful biomarker in breast cancer

Breast

Volumn 24, Issue , 2015, Pages S67-S72

  Denkert, Carsten ^a,b,c   Budczies, Jan ^a   von Minckwitz, Gunter ^c   Wienert, Stephan ^a,d   Loibl, Sibylle ^c   Klauschen, Frederick ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GERMAN BREAST GROUP   (Germany)

^d VMSCOPE GMBH   (Germany)

Author keywords

Gene expression profiling; Human breast carcinoma; Molecular pathology; Prognosis

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL PRACTICE; GENETIC HETEROGENEITY; HUMAN; INTEROBSERVER VARIABILITY; MOLECULAR DIAGNOSIS; OBSERVER VARIATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STANDARDIZATION; TOTAL QUALITY MANAGEMENT; VALIDATION PROCESS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; FEMALE; PROGNOSIS; REFERENCE VALUE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; OBSERVER VARIATION; PROGNOSIS; REFERENCE VALUES;

EID: 84948719218     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.07.017     Document Type: Article

References (28)

1. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31:13-20.
2. Lopez F., Belloc F., Lacombe F., Dumain P., Reiffers J., Bernard P., et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991, 12(1):42-49.
3. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011 Aug, 22(8):1736-1747. Panel Members.
4. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013 Sep, 24(9):2206-2223. Panel Members.
5. Dowsett M., Nielsen T.O., A'Hern R., Bartlett J., Coombes R.C., Cuzick J., et al. International Ki-67 in breast Cancer working group. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664.
6. Polley M.Y., Leung S.C., Gao D., Mastropasqua M.G., Zabaglo L.A., Bartlett J.M., et al. An international study to increase concordance in Ki67 scoring. Mod Pathol 2015 Jun, 28(6):778-786.
7. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005, 23:7212-7220.
8. de Azambuja E., Cardoso F., de Castro G., Colozza M., Mano M.S., Durbecq V., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513.
9. Yerushalmi R., Woods R., Ravdin P.M., Hayes M.M., Gelmon K.A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010, 11:174-183.
10. Stuart-Harris R., Caldas C., Pinder S.E., Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 2008, 17:323-334.
11. Luporsi E., André F., Spyratos F., Martin P.M., Jacquemier J., Penault-Llorca F., et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012, 132:895-915.
12. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005 Aug 17, 97(16):1180-1184.
13. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009 Nov 4, 101(21):1446-1452.
14. Fasching P.A., Heusinger K., Haeberle L., Niklos M., Hein A., Bayer C.M., et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011, 11:486.
15. Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'Orto P., et al. Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008 Dec 1, 26(34):5569-5575.
16. Penault-Llorca F., André F., Sagan C., Lacroix-Triki M., Denoux Y., Verriele V., et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009 Jun 10, 27(17):2809-2815.
17. Dumontet C., Krajewska M., Treilleux I., Mackey J.R., Martin M., Rupin M., et al. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010 Aug 1, 16(15):3988-3997.
18. Denkert C., Loibl S., Müller B.M., Eidtmann H., Schmitt W.D., Eiermann W., et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 2013 Nov, 24(11):2786-2793.
19. von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012 May 20, 30(15):1796-1804.
20. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014 Jul 12, 384(9938):164-172.
21. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009 Aug, 20(8):1319-1329. Panel Members.
22. Cserni G., Vörös A., Liepniece-Karele I., Bianchi S., Vezzosi V., Grabau D., et al. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast 2014 Jun, 23(3):259-263.
23. Dowsett M., Smith I.E., Ebbs S.R., et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170.
24. Dowsett M., Smith I.E., Ebbs S.R., Dixon J.M., Skene A., Griffith C., et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005, 11:951s-958s.
25. Minckwitz G., Schmitt W.D., Loibl S., Müller B.M., Blohmer J.U., Sinn B.V., et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013 Aug 15, 19(16):4521-4531.
26. Polley M.Y., Leung S.C., McShane L.M., Gao D., Hugh J.C., Mastropasqua M.G., et al. International Ki67 in breast cancer working group of the breast international group and North American breast Cancer group. An international Ki67 reproducibility study. J Natl Cancer Inst 2013 Dec 18, 105(24):1897-1906.
27. Klauschen F., Wienert S., Schmitt W., Loibl S., Gerber B., Blohmer J.U., et al. Standardized Ki67 diagnostics using automated scoring - clinical validation in the GeparTrio breast cancer study. Clin Cancer Res 2014 Dec 11.
28. Varga Z., Diebold J., Dommann-Scherrer C., Frick H., Kaup D., Noske A., et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 2012, 7:e37379.